Weekly Top News – Psoriasis – July 8, 2019

July 8, 2019

bimekizumab (UCB4940) / UCB
BE VITAL: A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) – Jul 5, 2019 – P3; N=1045; Not yet recruiting; Sponsor: UCB Biopharma S.P.R.L.


Enstilar (calcipotriene/betamethasone dipropionate) / Leo Pharma
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris (clinicaltrials.gov) – Jul 5, 2019 – P3; N=722; Completed; Sponsor: LEO Pharma; Active, not recruiting –> Completed


mirikizumab (LY3074828) / Eli Lilly
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) (clinicaltrials.gov) – Jul 5, 2019 – P3; N=1443; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting –> Active, not recruiting


Taltz (ixekizumab) / Eli Lilly
Taltz pricing: Wholesale acquisition cost of $5,162/Injection (J.P. Morgan) – Jul 5, 2019 – A subscription to Thomson ONE is required to gain full access to report 67530491; Page no: 20; REPORT TITLE: “European Pharmaceuticals: Weekly chartbook: TRx for week ending June 14th”; AUTHOR: Vosser, Richard, et al; DATE: 06/24/2019


BMS-986165 / BMS
BMS-986165 clinical trial estimate: Completition of P3 trials POETYK-PSO-1 (NCT03624127) and POETYK-PSO-2 (NCT03611751) for moderate-to-severe plaque psoriasis by late-2020 (RBC Capital Markets (Canada)) – Jul 3, 2019 – A subscription to Thomson ONE is required to gain full access to report 67512769; Page no: 22; REPORT TITLE: “Game Changers: Disruptive forces in biotech: 2H19 edition (v3.0)”; AUTHOR: Abrahams, Brian, et al; DATE: 06/19/2019


ABP 710 (infliximab biosimilar) / Amgen
Amgen pulls European application for its biosimilar infliximab ABP 710 (Center for Biosimilars) – Jul 1, 2019 – “Amgen has informed the European Medicines Agency (EMA) it is withdrawing its application for ABP 710, its biosimilar infliximab (Remicade). According to the letter sent to the EMA, Amgen said the decision was due to a change in product strategy.”


Otezla (apremilast) / Celgene
Otezla sales projection: $2.3B (consensus: $2.5B) in 2024 (Guggenheim) – Jul 3, 2019 – A subscription to Thomson ONE is required to gain full access to report 67532791; Page no: 1; REPORT TITLE: “Bristol-Myers Squibb Co. – BMY – They’re not gonna give Otezla away…but need to sell adds uncertainty & impacts timing”; AUTHOR: Fernandez, Seamus, et al; DATE: 06/25/2019


Taltz (ixekizumab) / Eli Lilly
Eli Lilly Korea gains further reimbursement for psoriasis treatment Taltz (Korea Biomedical Review) – Jul 1, 2019 – “The Korean branch of Eli Lilly said that it had gained additional reimbursement for its psoriasis treatment Taltz (Ingredient: ixekizumab) for treating active and progressive psoriatic arthritis from the Ministry of Health and Welfare.”


PF-06700841 / Pfizer
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) – Jul 1, 2019 – P2b; N=196; Recruiting; Sponsor: Pfizer; Not yet recruiting –> Recruiting

No Comments

Post a Comment